ILMN

Illumina, Inc.

September 15, 2026 · intraday

Rarity

1.79

Peak move

+8.80%

Float cap

$31.8B

Illumina provides sequencing- and array-based solutions for genetic and genomic analysis. Its integrated systems, consumables, and analysis tools are used by genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical and biotechnology companies, diagnostic laboratories, and consumer genomics firms. The company serves research, applied, and clinical markets, including oncology, genetic health, and reproductive health.

• major_contracttime: see source

  Novacyt S.A. entered a five-year Master Collaboration Agreement with Illumina, creating a framework for separate project-based product development and commercial deals without upfront capital commitments.

  Websimplywall.st
• index_rebalanceSep 13 · 17:50 ET

  S&P Dow Jones Indices announced Illumina will replace Builders FirstSource in the S&P 500 before the market opens on September 21, 2026, moving up from the S&P MidCap 400 as part of the quarterly rebalance, about 27 months after S&P Dow Jones Indices removed it on June 24, 2024, when it spun off GRAIL.

  Webtikr.comWebtikr.comWebbarchart.comWebweissratings.comWebpress.spglobal.com
• analyst_ratingSep 9 · 19:32 ET

  UBS upgraded Illumina to Buy from Neutral and raised its price target to $260 from $135.

  Webnasdaq.com
• insider_saleSep 8

  Illumina director Keith Meister sold 263,560 ILMN shares for about $57.19 million between September 2 and September 4 at prices of roughly $213 to $221.55 through Corvex Management funds, and filed a Form 144 to sell 150,000 shares via Goldman Sachs.

  Webmarkets.businessinsider.com